Valley National Advisers’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.45M | Buy |
5,759
+169
| +3% | +$36.4K | 0.16% | 115 |
|
|
2026
Q1 | $1.22M | Sell |
5,590
-53
| -0.9% | -$11.8K | 0.16% | 127 |
|
|
2025
Q4 | $1.29M | Buy |
5,643
+23
| +0.4% | +$5.24K | 0.18% | 121 |
|
|
2025
Q3 | $1.3M | Buy |
5,620
+12
| +0.2% | +$2.44K | 0.2% | 114 |
|
|
2025
Q2 | $1.04M | Buy |
5,608
+97
| +2% | +$18K | 0.17% | 128 |
|
|
2025
Q1 | $1.15M | Buy |
5,511
+406
| +8% | +$78.9K | 0.21% | 119 |
|
|
2024
Q4 | $907K | Buy |
5,105
+111
| +2% | +$20.4K | 0.16% | 126 |
|
|
2024
Q3 | $986K | Sell |
4,994
-677
| -12% | -$126K | 0.18% | 128 |
|
|
2024
Q2 | $972K | Buy |
5,671
+64
| +1% | +$10.6K | 0.14% | 117 |
|
|
2024
Q1 | $1.02M | Buy |
5,607
+81
| +1% | +$14K | 0.15% | 116 |
|
|
2023
Q4 | $856K | Sell |
5,526
-1,150
| -17% | -$168K | 0.14% | 122 |
|
|
2023
Q3 | $995K | Sell |
6,676
-286
| -4% | -$42K | 0.17% | 104 |
|
|
2023
Q2 | $939K | Sell |
6,962
-179
| -3% | -$26.2K | 0.16% | 112 |
|
|
2023
Q1 | $1.17M | Buy |
7,141
+7
| +0.1% | +$1.07K | 0.21% | 93 |
|
|
2022
Q4 | $1.12M | Sell |
7,134
-329
| -4% | -$50.4K | 0.2% | 99 |
|
|
2022
Q3 | $1.08M | Buy |
7,463
+54
| +0.7% | +$7.75K | 0.22% | 93 |
|
|
2022
Q2 | $1.13M | Sell |
7,409
-5,199
| -41% | -$794K | 0.24% | 82 |
|
|
2022
Q1 | $2.04M | Buy |
12,608
+366
| +3% | +$53.2K | 0.39% | 61 |
|
|
2021
Q4 | $1.66M | Sell |
12,242
-10
| -0.1% | -$1.18K | 0.31% | 90 |
|
|
2021
Q3 | $1.32M | Sell |
12,252
-19
| -0.2% | -$2.17K | 0.24% | 100 |
|
|
2021
Q2 | $1.38M | Buy |
12,271
+110
| +0.9% | +$12.4K | 0.25% | 94 |
|
|
2021
Q1 | $1.32M | Buy |
12,161
+63
| +0.5% | +$6.74K | 0.26% | 95 |
|
|
2020
Q4 | $1.3M | Sell |
12,098
-689
| -5% | -$66.2K | 0.27% | 75 |
|
|
2020
Q3 | $1.12M | Buy |
12,787
+93
| +0.7% | +$8.76K | 0.26% | 66 |
|
|
2020
Q2 | $1.25M | Sell |
12,694
-26
| -0.2% | -$2.29K | 0.29% | 60 |
|
|
2020
Q1 | $969K | Sell |
12,720
-82
| -0.6% | -$6.99K | 0.27% | 71 |
|
|
2019
Q4 | $1.13M | Buy |
12,802
+252
| +2% | +$20.9K | 0.28% | 72 |
|
|
2019
Q3 | $950K | Buy |
12,550
+1,668
| +15% | +$114K | 0.26% | 77 |
|
|
2019
Q2 | $791K | Sell |
10,882
-208
| -2% | -$16.3K | 0.22% | 83 |
|
|
2019
Q1 | $894K | Sell |
11,090
-369
| -3% | -$30.2K | 0.26% | 76 |
|
|
2018
Q4 | $1.06M | Sell |
11,459
-362
| -3% | -$31.8K | 0.34% | 61 |
|
|
2018
Q3 | $1.12M | Sell |
11,821
-379
| -3% | -$35.9K | 0.39% | 61 |
|
|
2018
Q2 | $1.13M | Sell |
12,200
-264
| -2% | -$25.8K | 0.43% | 55 |
|
|
2018
Q1 | $1.18M | Sell |
12,464
-220
| -2% | -$24.2K | 0.44% | 52 |
|
|
2017
Q4 | $1.23M | Sell |
12,684
-1,571
| -11% | -$148K | 0.43% | 48 |
|
|
2017
Q3 | $1.27M | Sell |
14,255
-473
| -3% | -$36K | 0.43% | 42 |
|
|
2017
Q2 | $1.07M | Sell |
14,728
-1,103
| -7% | -$74.2K | 0.38% | 48 |
|
|
2017
Q1 | $1.03M | Sell |
15,831
-5,083
| -24% | -$320K | 0.39% | 53 |
|
|
2016
Q4 | $1.31M | Sell |
20,914
-726
| -3% | -$44.3K | 0.6% | 48 |
|
|
2016
Q3 | $1.36M | Sell |
21,640
-29
| -0.1% | -$1.88K | 0.71% | 43 |
|
|
2016
Q2 | $1.34M | Sell |
21,669
-466
| -2% | -$28.4K | 0.7% | 45 |
|
|
2016
Q1 | $1.26M | Buy |
22,135
+1,035
| +5% | +$57.7K | 0.68% | 45 |
|
|
2015
Q4 | $1.25M | Sell |
21,100
-187
| -0.9% | -$10.8K | 0.74% | 40 |
|
|
2015
Q3 | $1.16M | Sell |
21,287
-85
| -0.4% | -$5.53K | 0.7% | 47 |
|
|
2015
Q2 | $1.44M | Sell |
21,372
-67
| -0.3% | -$4.37K | 0.81% | 37 |
|
|
2015
Q1 | $1.25M | Buy |
21,439
+858
| +4% | +$51.8K | 0.74% | 42 |
|
|
2014
Q4 | $1.09M | Buy |
+20,581
| New | +$1.3M | 0.82% | 37 |
|
Other funds holding ABBV
Valley National Advisers's ABBV Position: Q2 2026 in Review
Valley National Advisers increased its AbbVie (ABBV) stake by 3% in Q2 2026, buying an estimated $36.4K and bringing the position to 5,759 shares worth $1.45M. The position accounts for 0.16% of the portfolio, ranked #115.
Valley National Advisers first reported a position in ABBV in Q4 2014 and has held it in 47 quarters since. The position peaked at $2.04M in Q1 2022. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Valley National Advisers held 5,759 shares of AbbVie worth $1.45M as of Q2 2026.
- Valley National Advisers bought 169 AbbVie shares in Q2 2026, an estimated $36.4K.
- AbbVie made up 0.16% of Valley National Advisers's portfolio in Q2 2026, its #115 holding.
- Valley National Advisers first reported a position in AbbVie in Q4 2014 and has held it in 47 quarters since.
- Valley National Advisers's AbbVie position peaked at $2.04M in Q1 2022.
- 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Valley National Advisers's 13F filing for Q2 2026, filed 29 Jul 2026.